Spruce Biosciences, Inc. (SPRB)

Market Cap	5.36M
Revenue (ttm)	1.30M
Net Income (ttm)	-48.34M
Shares Out	563.04K
EPS (ttm)	-84.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,882
Open	9.50
Previous Close	9.58
Day's Range	8.87 - 10.10
52-Week Range	4.28 - 45.60
Beta	2.43
Analysts	Hold
Price Target	131.25 (+1,278.68%)
Earnings Date	Nov 10, 2025

About SPRB

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sle...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 21
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRB
• Website: https://sprucebio.com

Financial Performance

In 2024, Spruce Biosciences's revenue was $4.91 million, a decrease of -51.32% compared to the previous year's $10.09 million. Losses were -$53.04 million, 10.7% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for SPRB stock is "Hold." The 12-month stock price target is $131.25, which is an increase of 1,278.68% from the latest price.

Price Target

$131.25

(1,278.68% upside)

Analyst Consensus: Hold